ABSTRACT
4. Summary
In conclusion, smart materials, especially nanomedicine, are currently one of the leading directions in cancer research. It offers a broad range of advantages to improve the quality of clinical prognosis. Furthermore, smart materials can serve as multifunctional drug delivery systems that exhibit exceptional therapeutic properties over traditional chemotherapeutics.
Meanwhile, owing to the unique optical/magnetic properties, many inorganic smart nanomedicines can be used as novel molecular imaging contrast agents to improve early detection and diagnosis of cancer.
Combining smart nanomedicine’s advantages, we believe that, in the near future, tumor-targeting nanotechnology will revolutionize the fi eld of cancer research by signifi cantly enhancing tumor detection accuracy, therapeutic sensitivity and effi ciency, and subsequently improve cancer prognosis outcomes.
References
Abdalla, M.O., P. Karna, H.K. Sajja, H. Mao, C. Yates, T. Turner and R. Aneja. 2011. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J. Control. Release Off. J. Control. Release Soc. 149: 314–322.
Acharya, S., F. Dilnawaz and S.K. Sahoo. 2009. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 30: 5737–5750.
Aggarwal, S., S. Yadav and S. Gupta. 2011. EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer. J. Biomed. Nanotechnol. 7: 137–138.
Amado, R.G., M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D.J. Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky, S.D. Patterson and D.D. Chang. 2008. Wild-Type KRAS is required for panitumumab effi cacy in patients with metastatic colorectal cancer. J. Clin. Oncol.
26: 1626–1634.
Audeh, M.W., J. Carmichael, R.T. Penson, M. Friedlander, B. Powell, K.M. Bell-McGuinn, C. Scott, J.N. Weitzel, A. Oaknin, N. Loman, K. Lu, R.K. Schmutzler, U. Matulonis,
M. Wickens and A. Tutt. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of- concept trial. The Lancet 376: 245–251.
Bagalkot, V., O.C. Farokhzad, R. Langer and S. Jon. 2006. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed Engl.
45: 8149–8152.
Banerjee, R., P. Tyagi, S. Li and L. Huang. 2004. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer J.
Int. Cancer 112: 693–700.
Bang, Y.J., E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Rüschoff and Y.-K. Kang. 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet 376: 687–697.
Barenholz, Y. 2012. Doxil®—The fi rst FDA-approved nano-drug: Lessons learned. J. Controlled Release 160: 117–134.
Barnett, B.P., A. Arepally, P.V. Karmarkar, D. Qian, W.D. Gilson, P. Walczak, V. Howland, L. Lawler, C. Lauzon, M. Stuber, D.L. Kraitchman and J.W.M. Bulte. 2007. Magnetic resonance–guided, real-time targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells. Nat. Med. 13: 986–991.
Barth, B.M., R. Sharma, E.I. Altinoğlu, T.T. Morgan, S.S. Shanmugavelandy, J.M. Kaiser, C. McGovern, G.L. Matters, J.P. Smith, M. Kester and J.H. Adair. 2010. Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano 4: 1279–1287.
Baselga, J., M. Campone, M. Piccart, H.A. Burris, H.S. Rugo, T. Sahmoud, S. Noguchi, M.
Gnant, K.I. Pritchard, F. Lebrun, J.T. Beck, Y. Ito, D. Yardley, I. Deleu, A. Perez, T. Bachelot, L. Vittori, Z. Xu, P. Mukhopadhyay, D. Lebwohl and G.N. Hortobagyi. 2012a. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N. Engl. J. Med.
366: 520–529.
Baselga, J., J. Cortés, S.B. Kim, S.A. Im, R. Hegg, Y.H. Im, L. Roman, J.L. Pedrini, T. Pienkowski, A. Knott, E. Clark, M.C. Benyunes, G. Ross and S.M. Swain. 2012b. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366: 109–119.
Benezra, M., O. Penate-Medina, P.B. Zanzonico, D. Schaer, H. Ow, A. Burns, E. DeStanchina, V. Longo, E. Herz, S. Iyer, J. Wolchok, S.M. Larson, U. Wiesner and M.S. Bradbury. 2011.
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest. 121: 2768–2780.
Boles, K.S., A.H. Schmieder, A.W. Koch, R.A.D. Carano, Y. Wu, S.D. Caruthers, R.K. Tong, S. Stawicki, G. Hu, M.J. Scott, H. Zhang, B.A. Reynolds, S.A. Wickline and G.M. Lanza.
2010. MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J. 24: 4262–4270.
Cabot, R.C., N.L. Harris, E.S. Rosenberg, J.A.O. Shepard, A.M. Cort, S.H. Ebeling, E.K. McDonald, H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, R. de Wit, P. Mulders, K.N. Chi, N.D. Shore, A.J. Armstrong, T.W. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J.D. Hainsworth, M. Hirmand, B. Selby, L. Seely and J.S. de Bono. 2012. Increased survival with enzalutamide in prostate cancer after chemotherapy.
N. Engl. J. Med. 367: 1187–1197.
Camp, E.R., C. Wang, E.C. Little, P.M. Watson, K.F. Pirollo, A. Rait, D.J. Cole, E.H. Chang and D.K. Watson. 2013. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 20: 222–228.
Chapman, P.B., A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S.J. O’Day, J.A. Sosman, J.M. Kirkwood, A.M.M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R.J. Lee, K.T. Flaherty and G.A. McArthur. 2011.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
N. Engl. J. Med. 364: 2507–2516.
Cheng, A.L., Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, J.S. Kim, R. Luo, J. Feng, S. Ye, T.S. Yang, J. Xu, Y. Sun, H. Liang, J. Liu, J. Wang, W.Y. Tak, H. Pan, K. Burock, J. Zou, D. Voliotis and Z. Guan. 2009. Effi cacy and safety of sorafenib in patients in the Asia-Pacifi c region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo- controlled trial. Lancet Oncol. 10: 25–34.
Cheng, J., B.A. Teply, I. Sherifi , J. Sung, G. Luther, F.X. Gu, E. Levy-Nissenbaum, A.F. Radovic- Moreno, R. Langer and O.C. Farokhzad. 2007. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28: 869–876.
Chen, Y., S.R. Bathula, Q. Yang and L. Huang. 2010. Targeted nanoparticles deliver siRNA to melanoma. J. Invest. Dermatol. 130: 2790–2798.
Chen, Y., W. Wang, G. Lian, C. Qian, L. Wang, L. Zeng, C. Liao, B. Liang, B. Huang, K. Huang and X. Shuai. 2012. Development of an MRI-visible nonviral vector for siRNA delivery targeting gastric cancer. Int. J. Nanomedicine 7: 359–368.
Cho, Y.S., T.J. Yoon, E.S. Jang, K. Soo Hong, S. Young Lee, O. Ran Kim, C. Park, Y.J. Kim, G.C. Yi and K. Chang. 2010. Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging. Cancer Lett. 299: 63–71.
Cirstoiu-Hapca, A., F. Buchegger, N. Lange, L. Bossy, R. Gurny and F. Delie. 2010. Benefi t of anti- HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic effi cacy and biodistribution in mice. J. Control. Release Off.
J. Control. Release Soc. 144: 324–331.
Cunningham, D., Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau and E. Van Cutsem. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
N. Engl. J. Med. 351: 337–345.
De Bono, J.S., C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman, F. Saad, J.N. Staffurth, P. Mainwaring, S. Harland, T.W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C.N. Sternberg, S.L. Ellard, A. Fléchon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C.M. Haqq and H.I. Scher. 2011. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364: 1995–2005.
De Bono, J.S., S. Oudard, M. Ozguroglu, S. Hansen, J.P. Machiels, I. Kocak, G. Gravis, I. Bodrogi, M.J. Mackenzie, L. Shen, M. Roessner, S. Gupta and A.O. Sartor. 2010. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet 376: 1147–1154.
Dhar, S., F.X. Gu, R. Langer, O.C. Farokhzad and S.J. Lippard. 2008. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 105: 17356–17361.
El-Sayed, I.H., X. Huang and M.A. El-Sayed. 2006. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 239: 129–135.
Esmaeili, F., M.H. Ghahremani, S.N. Ostad, F. Atyabi, M. Seyedabadi, M.R. Malekshahi, M. Amini and R. Dinarvand. 2008. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J. Drug Target. 16: 415–423.
Falchook, G.S., K.D. Lewis, J.R. Infante, M.S. Gordon, N.J. Vogelzang, D.J. DeMarini, P. Sun, C. Moy, S.A. Szabo, L.T. Roadcap, V.G. Peddareddigari, P.F. Lebowitz, N.T. Le, H.A.
Burris, W.A. Messersmith, P.J. O’Dwyer, K.B. Kim, K. Flaherty, J.C. Bendell, R. Gonzalez, R. Kurzrock and L.A. Fecher. 2012. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 13: 782–789.
Fan, L., F. Li, H. Zhang, Y. Wang, C. Cheng, X. Li, C.H. Gu, Q. Yang, H. Wu and S. Zhang.
2010. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials 31: 5634–5642.
Farokhzad, O.C., J. Cheng, B.A. Teply, I. Sherifi , S. Jon, P.W. Kantoff, J.P. Richie and R. Langer.
2006. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
Proc. Natl. Acad. Sci. U.S.A. 103: 6315–6320.
Farokhzad, O.C., S. Jon, A. Khademhosseini, T.N.T. Tran, D.A. Lavan and R. Langer. 2004.
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Cancer Res. 64: 7668–7672.
Ferlay, J., I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman and F. Bray. 2015. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int. J. Cancer 136: E359–E386.
Finn, R.S., J.P. Crown, I. Lang, K. Boer, I.M. Bondarenko, S.O. Kulyk, J. Ettl, R. Patel, T. Pinter, M. Schmidt, Y. Shparyk, A.R. Thummala, N.L. Voytko, C. Fowst, X. Huang, S.T. Kim, S. Randolph and D.J. Slamon. 2015. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as fi rst-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16: 25–35.
Friedman, H.S., M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, L.E. Abrey, W.K.A. Yung, N. Paleologos, M.K. Nicholas, R. Jensen, J. Vredenburgh, J. Huang, M. Zheng and T. Cloughesy. 2009. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27: 4733–4740.
Fuchs, C.S., J. Tomasek, C.J. Yong, F. Dumitru, R. Passalacqua, C. Goswami, H. Safran, L.V. dos Santos, G. Aprile, D.R. Ferry, B. Melichar, M. Tehfe, E. Topuzov, J.R. Zalcberg, I. Chau, W. Campbell, C. Sivanandan, J. Pikiel, M. Koshiji, Y. Hsu, A.M. Liepa, L. Gao, J.D. Schwartz and J. Tabernero. 2014. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 383: 31–39.
Gan, C.W. and S.-S. Feng. 2010. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha- tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 31: 7748–7757.
Ganti, A.K. 2006. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J. Clin. Oncol. 24: 59–63.
Garon, E.B., D. Cao, E. Alexandris, W.J. John, S. Yurasov and M. Perol. 2012. A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non–small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clin.
Lung Cancer 13: 505–509.
Geyer, C.E., J. Forster, D. Lindquist, S. Chan, C.G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. Skarlos, M. Campone, N. Davidson, M. Berger, C. Oliva, S.D. Rubin, S. Stein and D. Cameron. 2006. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355: 2733–2743.
Glazer, E.S., C. Zhu, K.L. Massey, C.S. Thompson, W.D. Kaluarachchi, A.N. Hamir and S.A. Curley. 2010. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin. Cancer Res.
Off. J. Am. Assoc. Cancer Res. 16: 5712–5721.
Green, M.R. 2006. Abraxane(R), a novel Cremophor(R)-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol.
17: 1263–1268.
Grothey, A., E.V. Cutsem, A. Sobrero, S. Siena, A. Falcone, M. Ychou, Y. Humblet, O. Bouché, L. Mineur, C. Barone, A. Adenis, J. Tabernero, T. Yoshino, H.J. Lenz, R.M. Goldberg, D.J. Sargent, F. Cihon, L. Cupit, A. Wagner and D. Laurent. 2013. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet 381: 303–312.
Gu, J., S. Su, M. Zhu, Y. Li, W. Zhao, Y. Duan and J. Shi. 2012. Targeted doxorubicin delivery to liver cancer cells by PEGylated mesoporous silica nanoparticles with a pH-dependent release profi le. Microporous Mesoporous Mater. 161: 160–167.
Gupta, B. and V.P. Torchilin. 2007. Monoclonal antibody 2C5-modifi ed doxorubicin-loaded liposomes with signifi cantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol. Immunother. CII 56: 1215–1223.
Guthi, J.S., S.G. Yang, G. Huang, S. Li, C. Khemtong, C.W. Kessinger, M. Peyton, J.D. Minna, K.C. Brown and J. Gao. 2010. MRI-Visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol. Pharm. 7: 32–40.
Hadjipanayis, C.G., R. Machaidze, M. Kaluzova, L. Wang, A.J. Schuette, H. Chen, X. Wu and H. Mao. 2010. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 70: 6303–6312.
Hattori, Y. and Y. Maitani. 2005. Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase. Cancer Gene Ther. 12: 796–809.
Hattori, Y. and Y. Maitani. 2004. Enhanced in vitro DNA transfection effi ciency by novel folate- linked nanoparticles in human prostate cancer and oral cancer. J. Control. Release Off.
J. Control. Release Soc. 97: 173–183.
Hauschild, A., J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, M. Millward, P. Rutkowski, C.U. Blank, W.H. Miller, E. Kaempgen, S. Martín-Algarra, B. Karaszewska, C. Mauch, V. Chiarion-Sileni, A.M. Martin, S. Swann, P. Haney, B. Mirakhur, M.E. Guckert, V. Goodman and P.B. Chapman. 2012. Dabrafenib in BRAF-mutated metastatic melanoma:
a multicentre, open-label, phase 3 randomised controlled trial. The Lancet 380: 358–365.
Hölig, P., M. Bach, T. Völkel, T. Nahde, S. Hoffmann, R. Müller and R.E. Kontermann. 2004.
Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng. Des. Sel. PEDS 17: 433–441.
Hsieh, W.J., C.J. Liang, J.J. Chieh, S.H. Wang, I.R. Lai, J.H. Chen, F.H. Chang, W.K. Tseng, S.Y. Yang, C.C. Wang and Y.L. Chen. 2012. In vivo tumor targeting and imaging with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles. Int. J. Nanomedicine 2833.
Huang, G., C. Zhang, S. Li, C. Khemtong, S.G. Yang, R. Tian, J.D. Minna, K.C. Brown and J. Gao. 2009. A novel strategy for surface modifi cation of superparamagnetic iron oxide nanoparticles for lung cancer imaging. J. Mater. Chem. 19: 6367–6372.
Hurwitz, H., L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross and F. Kabbinavar. 2004. Bevacizumab plus irinotecan, fl uorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350: 2335–2342.
Iinuma, H., K. Maruyama, K. Okinaga, K. Sasaki, T. Sekine, O. Ishida, N. Ogiwara, K. Johkura and Y. Yonemura. 2002. Intracellular targeting therapy of cisplatin- encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int. J. Cancer J. Int. Cancer 99: 130–137.
Jain, A., S.K. Jain, N. Ganesh, J. Barve and A.M. Beg. 2010. Design and development of ligand- appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer.
Nanomedicine Nanotechnol. Biol. Med. 6: 179–190.
Jin, Y.J., U. Termsarasab, S.H. Ko, J.S. Shim, S. Chong, S.J. Chung, C.K. Shim, H.J. Cho and D.D. Kim. 2012. Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma. Pharm. Res. 29: 3443–3454.
Ji, Z., G. Lin, Q. Lu, L. Meng, X. Shen, L. Dong, C. Fu and X. Zhang. 2012. Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. J. Colloid Interface Sci. 365: 143–149.
Kamaly, N., T. Kalber, M. Thanou, J.D. Bell and A.D. Miller. 2009. Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging. Bioconjug. Chem. 20: 648–655.
Kantoff, P.W., C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, D.F. Penson, C.H. Redfern, A.C. Ferrari, R. Dreicer, R.B. Sims, Y. Xu, M.W. Frohlich and P.F. Schellhammer. 2010.
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.
363: 411–422.
Kikumori, T., T. Kobayashi, M. Sawaki and T. Imai. 2009. Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Res. Treat. 113: 435–441.
Kim, D., Z.G. Gao, E.S. Lee and Y.H. Bae. 2009. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol. Pharm. 6: 1353–1362.
Kinsella, J.M., R.E. Jimenez, P.P. Karmali, A.M. Rush, V.R. Kotamraju, N.C. Gianneschi, E. Ruoslahti, D. Stupack and M.J. Sailor. 2011. X-Ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfi de nanoparticles. Angew.
Chem. Int. Ed. 50: 12308–12311.
Klutz, K., D. Schaffert, M.J. Willhauck, G.K. Grünwald, R. Haase, N. Wunderlich, C. Zach, F.J. Gildehaus, R. Senekowitsch-Schmidtke, B. Göke, E. Wagner, M. Ogris and C. Spitzweg.
2011. Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. Mol. Ther. J. Am. Soc. Gene Ther. 19: 676–685.
Krueger, D.A., M.M. Care, K. Holland, K. Agricola, C. Tudor, P. Mangeshkar, K.A. Wilson, A. Byars, T. Sahmoud and D.N. Franz. 2010. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363: 1801–1811.
Lee, G.Y., W.P. Qian, L. Wang, Y.A. Wang, C.A. Staley, M. Satpathy, S. Nie, H. Mao and L. Yang. 2013. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano 7: 2078–2089.
Lee, J.H., Y.M. Huh, Y. Jun, J. Seo, J. Jang, H.T. Song, S. Kim, E.J. Cho, H.G. Yoon, J.S. Suh and J. Cheon. 2007. Artifi cially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat. Med. 13: 95–99.
Liang, H.F., C.T. Chen, S.C. Chen, A.R. Kulkarni, Y.L. Chiu, M.C. Chen and H.W. Sung. 2006.
Paclitaxel-loaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials 27: 2051–2059.
Li, S.D. and L. Huang. 2006. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol. Pharm. 3: 579–588.
Liu, M., Z.H. Li, F.J. Xu, L.H. Lai, Q.Q. Wang, G.P. Tang and W.T. Yang. 2012. An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy.
Biomaterials 33: 2240–2250.
Liu, Y., Z. Chen, C. Liu, D. Yu, Z. Lu and N. Zhang. 2011. Gadolinium-loaded polymeric nanoparticles modifi ed with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer. Biomaterials 32: 5167–5176.
Li, W., H. Zhao, W. Qian, H. Li, L. Zhang, Z. Ye, G. Zhang, M. Xia, J. Li, J. Gao, B. Li, G. Kou, J. Dai, H. Wang and Y. Guo. 2012. Chemotherapy for gastric cancer by fi nely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials 33: 5349–5362.
Löw, K., M. Wacker, S. Wagner, K. Langer and H. von Briesen. 2011. Targeted human serum albumin nanoparticles for specifi c uptake in EGFR-Expressing colon carcinoma cells.
Nanomedicine Nanotechnol. Biol. Med. 7: 454–463.
Madhankumar, A.B., B. Slagle-Webb, X. Wang, Q.X. Yang, D.A. Antonetti, P.A. Miller, J.M. Sheehan and J.R. Connor. 2009. Effi cacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol. Cancer Ther. 8: 648–654.
Maeng, J.H., D.H. Lee, K.H. Jung, Y.H. Bae, I.S. Park, S. Jeong, Y.S. Jeon, C.K. Shim, W. Kim, J. Kim, J. Lee, Y.M. Lee, J.H. Kim, W.H. Kim and S.S. Hong. 2010. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials 31: 4995–5006.
Magadala, P. and M. Amiji. 2008. Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J. 10: 565–576.
Matsui, M., Y. Shimizu, Y. Kodera, E. Kondo, Y. Ikehara and H. Nakanishi. 2010. Targeted delivery of oligomannose-coated liposome to the omental micrometastasis by peritoneal macrophages from patients with gastric cancer. Cancer Sci. 101: 1670–1677.
Mehlen, P. and A. Puisieux. 2006. Metastasis: a question of life or death. Nat. Rev. Cancer 6: 449–458.
Miller, V.A., V. Hirsh, J. Cadranel, Y.M. Chen, K. Park, S.W. Kim, C. Zhou, W.C. Su, M. Wang, Y. Sun, D.S. Heo, L. Crino, E.H. Tan, T.Y. Chao, M. Shahidi, X.J. Cong, R.M. Lorence and J.C.H. Yang. 2012. Afatinib versus placebo for patients with advanced, metastatic non- small-cell lung cancer after failure of erlotinib, gefi tinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 13: 528–538.
Moore, M.J., D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, S. Gallinger, H.J. Au, P. Murawa, D. Walde, R.A. Wolff, D. Campos, R. Lim, K. Ding, G. Clark, T. Voskoglou-Nomikos, M. Ptasynski and W. Parulekar. 2007. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group. J. Clin. Oncol. 25: 1960–1966.
Nigam, P., S. Waghmode, M. Louis, S. Wangnoo, P. Chavan and D. Sarkar. 2014. Graphene quantum dots conjugated albumin nanoparticles for targeted drug delivery and imaging of pancreatic cancer. J. Mater. Chem. B 2, 3190.
Nukolova, N.V., H.S. Oberoi, S.M. Cohen, A.V. Kabanov and T.K. Bronich. 2011. Folate- decorated nanogels for targeted therapy of ovarian cancer. Biomaterials 32: 5417–5426.
Pan, L., M. He, J. Ma, W. Tang, G. Gao, R. He, H. Su and D. Cui. 2013. Phase and size controllable synthesis of NaYbF4 nanocrystals in oleic acid/ionic liquid two-phase system for targeted fl uorescent imaging of gastric cancer. Theranostics 3: 210–222.
Patra, C.R., R. Bhattacharya, E. Wang, A. Katarya, J.S. Lau, S. Dutta, M. Muders, S. Wang, S.A. Buhrow, S.L. Safgren, M.J. Yaszemski, J.M. Reid, M.M. Ames, P. Mukherjee and D. Mukhopadhyay. 2008. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 68: 1970–1978.
Peer, D. and R. Margalit. 2004. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia N. Y. N. 6: 343–353.
Peng, X.H., Y. Wang, D. Huang, Y. Wang, H.J. Shin, Z. Chen, M.B. Spewak, H. Mao, X. Wang, Y. Wang, Z. Chen (Georgia), S. Nie and D.M. Shin. 2011. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-Heparin-Cisplatin nanoparticles. ACS Nano 5: 9480–9493.
Perche, F., N.R. Patel and V.P. Torchilin. 2012. Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J. Control.
Release Off. J. Control. Release Soc. 164: 95–102.
Qian, X., X.H. Peng, D.O. Ansari, Q. Yin-Goen, G.Z. Chen, D.M. Shin, L. Yang, A.N. Young, M.D. Wang and S. Nie. 2008. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat. Biotechnol. 26: 83–90.
Rachakatla, R.S., S. Balivada, G.M. Seo, C.B. Myers, H. Wang, T.N. Samarakoon, R. Dani, M. Pyle, F.O. Kroh, B. Walker, X. Leaym, O.B. Koper, V. Chikan, S.H. Bossmann, M. Tamura and D.L. Troyer. 2010. Attenuation of mouse melanoma by A/C magnetic fi eld after delivery of bi-magnetic nanoparticles by neural progenitor cells. ACS Nano 4: 7093–7104.
Raymond, E., L. Dahan, J.L. Raoul, Y.J. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, J.S. Chen, D. Hörsch, P. Hammel, B. Wiedenmann, E. Van Cutsem, S. Patyna, D.R. Lu, C. Blanckmeister, R. Chao and P. Ruszniewski. 2011. Sunitinib Malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364: 501–513.
Reddy, G.R., M.S. Bhojani, P. McConville, J. Moody, B.A. Moffat, D.E. Hall, G. Kim, Y.E.L. Koo, M.J. Woolliscroft, J.V. Sugai, T.D. Johnson, M.A. Philbert, R. Kopelman, A. Rehemtulla and B.D. Ross. 2006. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 12: 6677–6686.
Ren, Y., H.W. Cheung, G. von Maltzhan, A. Agrawal, G.S. Cowley, B.A. Weir, J.S. Boehm, P. Tamayo, A.M. Karst, J.F. Liu, M.S. Hirsch, J.P. Mesirov, R. Drapkin, D.E. Root, J. Lo, V. Fogal, E. Ruoslahti, W.C. Hahn and S.N. Bhatia. 2012. Targeted tumor-penetrating
siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci. Transl.
Med. 4: 147ra112.
Romond, E.H., E.A. Perez, J. Bryant, V.J. Suman, C.E. Geyer, N.E. Davidson, E. Tan-Chiu, S. Martino, S. Paik, P.A. Kaufman, S.M. Swain, T.M. Pisansky, L. Fehrenbacher, L.A. Kutteh, V.G. Vogel, D.W. Visscher, G. Yothers, R.B. Jenkins, A.M. Brown, S.R. Dakhil, E.P. Mamounas, W.L. Lingle, P.M. Klein, J.N. Ingle and N. Wolmark. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.
353: 1673–1684.
Rozhkova, E.A., I. Ulasov, B. Lai, N.M. Dimitrijevic, M.S. Lesniak and T. Rajh. 2009. A high-performance nanobio photocatalyst for targeted brain cancer therapy. Nano Lett.
9: 3337–3342.
Ruan, J., J. Ji, H. Song, Q. Qian, K. Wang, C. Wang and D. Cui. 2012a. Fluorescent magnetic nanoparticle-labeled mesenchymal stem cells for targeted imaging and hyperthermia therapy of in vivo gastric cancer. Nanoscale Res. Lett. 7: 309.
Ruan, J., H. Song, Q. Qian, C. Li, K. Wang, C. Bao and D. Cui. 2012b. HER2 monoclonal antibody conjugated RNase-A-associated CdTe quantum dots for targeted imaging and therapy of gastric cancer. Biomaterials 33: 7093–7102.
Sadhukha, T., T.S. Wiedmann and J. Panyam. 2013. Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials 34: 5163–5171.
Sandler, A., R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, R. Lilenbaum and D.H. Johnson. 2006. Paclitaxel–Carboplatin alone or with bevacizumab for non–small-cell lung cancer. N. Engl. J. Med. 355: 2542–2550.
Santra, S., C. Kaittanis, J. Grimm and J.M. Perez. 2009. Drug/Dye-Loaded, Multifunctional Iron Oxide Nanoparticles for Combined Targeted Cancer Therapy and Dual Optical/
Magnetic Resonance Imaging. Small 5: 1862–1868.
Sato, S. and H. Itamochi. 2012. Bevacizumab and ovarian cancer: Curr. Opin. Obstet. Gynecol.
24: 8–13.
Sawant, R.M., M.B. Cohen, V.P. Torchilin and O.W. Rokhlin. 2008. Prostate cancer-specifi c monoclonal antibody 5D4 signifi cantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro. J. Drug Target. 16: 601–604.
Scarberry, K.E., E.B. Dickerson, Z.J. Zhang, B.B. Benigno and J.F. McDonald. 2010. Selective removal of ovarian cancer cells from human ascites fl uid using magnetic nanoparticles.
Nanomedicine Nanotechnol. Biol. Med. 6: 399–408.
Schmieder, A.H., P.M. Winter, S.D. Caruthers, T.D. Harris, T.A. Williams, J.S. Allen, E.K. Lacy, H. Zhang, M.J. Scott, G. Hu, J.D. Robertson, S.A. Wickline and G.M. Lanza. 2005. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn. Reson. Med. 53: 621–627.
Shaw, A.T., D.W. Kim, R. Mehra, D.S.W. Tan, E. Felip, L.Q.M. Chow, D.R. Camidge, J. Vansteenkiste, S. Sharma, T. De Pas, G.J. Riely, B.J. Solomon, J. Wolf, M. Thomas, M. Schuler, G. Liu, A. Santoro, Y.Y. Lau, M. Goldwasser, A.L. Boral and J.A. Engelman.
2014. Ceritinib in ALK—rearranged non–small-cell lung cancer. N. Engl. J. Med.
370: 1189–1197.
Shaw, A.T., D.W. Kim, K. Nakagawa, T. Seto, L. Crinó, M.J. Ahn, T. De Pas, B. Besse, B.J. Solomon, F. Blackhall, Y.L. Wu, M. Thomas, K.J. O’Byrne, D. Moro-Sibilot, D.R. Camidge, T. Mok, V. Hirsh, G.J. Riely, S. Iyer, V. Tassell, A. Polli, K.D. Wilner and P.A. Jänne. 2013. Crizotinib versus chemotherapy in advanced ALK—positive lung cancer.
N. Engl. J. Med. 368: 2385–2394.
Shen, Z., W. Wei, H. Tanaka, K. Kohama, G. Ma, T. Dobashi, Y. Maki, H. Wang, J. Bi and S. Dai.
2011. A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy.
Pharmacol. Res. Off. J. Ital. Pharmacol. Soc. 64: 410–419.
Shepherd, F.A., J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, M. van Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabárbara and L. Seymour. 2005.
Erlotinib in previously treated non–small-cell lung cancer. N. Engl. J. Med. 353: 123–132.